Saturday, May 10, 2025 11:46:52 AM
Do you see in the title the statement "For Delegated and Retained Prescribed Specialized Services"? That indicates what the list is for.
For any approved drug, in addition to the centralized funding by NHS England, IDF and CDF, it is possible for specific funding to be provided by delegated authorities. That is what this list is for. And it does not say they are by anybody, just that they need follow rules for expensive treatments if they are. It is possible for a drug NHS reimbursement to also be used and funded regionally for non-funded uses.
If you look at the line items in the spreadsheet, this is made clear. Look at the column "NICE TA/Policy" you will see some have links to a Technical Appraisal supporting funding. See the entry just under Murcidencel. OTOH, some just say "Not Routinely Commissioned" which indicates no such approval and is not funded by NHS/CDF/IDF.
This attempt to convince posters that Not Reimbursed means Reimbursed and Nonproprietary means proprietary is telling.
For any approved drug, in addition to the centralized funding by NHS England, IDF and CDF, it is possible for specific funding to be provided by delegated authorities. That is what this list is for. And it does not say they are by anybody, just that they need follow rules for expensive treatments if they are. It is possible for a drug NHS reimbursement to also be used and funded regionally for non-funded uses.
If you look at the line items in the spreadsheet, this is made clear. Look at the column "NICE TA/Policy" you will see some have links to a Technical Appraisal supporting funding. See the entry just under Murcidencel. OTOH, some just say "Not Routinely Commissioned" which indicates no such approval and is not funded by NHS/CDF/IDF.
This attempt to convince posters that Not Reimbursed means Reimbursed and Nonproprietary means proprietary is telling.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
